Plasma thrombin activatable fibrinolysis inhibitor levels in Behcet's disease

ÖZCAN M. A., Akar S., ALACACIOĞLU İ., Pişkin Ö., YÜKSEL F., Gürler O., ...Daha Fazla

TURKISH JOURNAL OF MEDICAL SCIENCES, cilt.37, sa.5, ss.267-271, 2007 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 37 Sayı: 5
  • Basım Tarihi: 2007
  • Dergi Adı: TURKISH JOURNAL OF MEDICAL SCIENCES
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.267-271
  • Anahtar Kelimeler: Behcet's disease, TAFI, fibrinolysis, coagulation, PROTEIN-S DEFICIENCY, FACTOR-V-LEIDEN, PROCARBOXYPEPTIDASE-U, THROMBOPHILIC FACTORS, VASCULAR INVOLVEMENT, COAGULATION, ANTIBODIES, MUTATION, TAFI
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Aim: The precise pathogenetic mechanisms causing thrombotic complications in Behcet's disease (BID) are still not known. To explain the pathogenesis with coagulation induction or a defective fibrinolysis superimposed on endothelial dysfunction, various hemostatic parameters were studied. Thrombin activatable fibrinolysis inhibitor (TAFI), downregulating plasmin generation and fibrinolysis, is a novel risk factor for thrombotic disorders. We studied plasma TAR levels in BD in comparison with healthy controls.